Combating Infections in the ICU: Dual Approach
Shinhye Cheon, Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, and colleagues, investigated the effectiveness of antimicrobial stewardship and intensified infection control measures for controlling endemic MDR A. baumannii in the 3 medical and surgical ICUs in Chungnam University Hospital in Korea (Cheon et al. 2016). Each ICU is a multi-bed open ward with one isolation bed.
Prior to the intervention, standard procedures included using gowns and gloves when dealing with infected patients, no restrictions on using antibiotics and cleaning using 0.01% sodium hypochlorite once a day.
See Also: Infection Prevention in the ICU
The infection control strategy comprised antimicrobial stewardship, hospital staff education that focused on when and how to perform hand hygiene, active surveillance cultures, contact precautions, environmental cleaning (increased from once to three times a day) and disinfection enforcement, including an additional worker assigned to perform an extra 2 hours of cleaning per day, as well as hand hygiene promotion. Carbapenems could be prescribed and renewed only with the approval of an infectious disease physician. Isolation using plastic curtains and contact precautions was applied to patients who were colonised or infected with MDR A. baumannii.
The outcome was measured as the incidence density rate of hospital-onset MDR A. baumannii among patients in the ICUs. Prior to the intervention the isolation rates of MDR A. baumannii had increased from 55.4% during January 2012 to 94.1% during March 2013, when the consumption of carbapenems was doubled.
The incidence density rate of hospital-onset MDR A. baumannii decreased from 22.82 cases per 1,000 patient-days to 2.68 cases per 1,000 patient-days after implementation of the intervention. The mean monthly use of carbapenems decreased from 134.99 ± 82.26 defined daily doses per 1,000 patient-days to 94.85 ± 50.98 defined daily doses per 1,000 patient-days. Use of piperacillin/tazobactam and ciprofloxacin increased as these antibiotics were prescribed as alternatives to carbapenems. The study also found no statistical difference in all-cause mortality rates, MDR A. baumannii-related deaths and average length of ICU stays before and after the implementation of strict antimicrobial stewardship.
Chlorhexidine Gluconate Bathing
A meta-analysis published in the Journal of Critical Care found that chlorhexidine gluconate bathing reduces healthcare-associated infections in intensive care units, including central line–associated bloodstream infection (CLABSI), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) (Kim et al. 2016). In addition a prolonged intervention period and concomitant nasal antibiotic use were associated with lower risks of MRSA acquisition.
The authors state that although the included studies had multiple heterogeneities in their
intervention and surveillance methods, these were only associated with a low to medium risk of bias.
Image credit: freeimages.com
Kim HY, Lee WK, Na S et al. (2016) The effects of chlorhexidine gluconate bathing on health care-associated infection in intensive care units: A meta-analysis. J Crit Care, 32:126-37. doi: 10.1016/j.jcrc.2015.11.011. Epub 2015 Dec 2.
Published on : Mon, 28 Mar 2016
The HAMILTON-C3 ventilator is a modular high-end ventilation solution for all patient groups. Offering a number of unique features, the HAMILTON-C3 is one of the first ventilators featuring the “Ventilation Autopilot” INTELLiVENT-ASV®. The HAMILTON-C3’s...
Features SV 300 is a state-of-the-art ventilator that’s simple to configure, easy to operate and versatile in use. It equips with extensive ventilation modes that can treats pediatric and adult patients with all acuity levels at ICUs and Intermediate...
The HAMILTON-T1 combines for the first time the functionality of a fully featured intensive care unit ventilator with the compactness and ruggedness required for transport. This is why the HAMILTON-T1 enables you to provide optimal ventilation therapy...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
User experience enhanced by leading technologies With state-of-the-art screen technology, BeneVision N-Series patient monitors deliver clear, multi-color, wide-format displays for users to capture and review information at a glance. With...